| 10.73 0.19 (1.8%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.23  |
1-year : | 15.63 |
| Resists | First : | 12.19 |
Second : | 13.39 |
| Pivot price | 11.47 |
|||
| Supports | First : | 10.25 |
Second : | 8.52 |
| MAs | MA(5) : | 10.77 |
MA(20) : | 11.58 |
| MA(100) : | 13.2 |
MA(250) : | 9.87  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 8.4 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 18.37 | Low : | 5.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TENX ] has closed above bottom band by 18.4%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.01 - 11.07 | 11.07 - 11.12 |
| Low: | 10.09 - 10.17 | 10.17 - 10.24 |
| Close: | 10.61 - 10.73 | 10.73 - 10.84 |
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Fri, 05 Jun 2026
T. Rowe Price discloses 586,990 Tenax shares (NASDAQ: TENX) in amended 13G - Stock Titan
Thu, 04 Jun 2026
Tenax Therapeutics (TENX) shareholders elect full board, ratify 2026 auditor - Stock Titan
Tue, 12 May 2026
Tenax Therapeutics: Q1 Earnings Snapshot - kare11.com
Tue, 12 May 2026
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings - Quiver Quantitative
Tue, 12 May 2026
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, 04 May 2026
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 84.2 (%) |
| Shares Short | 776 (K) |
| Shares Short P.Month | 194 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -51.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.61 |
| PEG Ratio | 1.4 |
| Price to Book value | 4.68 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|